Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$1.98 USD
-0.18 (-8.33%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.98 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GOSS 1.98 -0.18(-8.33%)
Will GOSS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates
Other News for GOSS
GOSS: Wedbush Raises Gossamer Bio Price Target to $5 Following Outperform Rating | GOSS Stock News
Gossamer Bio GAAP EPS of -$0.17 in-line, revenue of $11.49M beats by $6.08M
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expansion
Gossamer Bio reports Q2 EPS (17c) , consensus (18c)
BlackRock, Inc. Expands Holdings in Gossamer Bio Inc.